Study provides preliminary evidence for validity of new wearable alcohol monitors

Alcohol biosensors suitable for use by everyday drinkers are a step closer, following a positive study of prototype devices published in the journal Alcoholism: Clinical & Experimental Research. Keeping track of alcohol intake can be challenging, given variation in standard drink sizes and impaired awareness as blood alcohol levels rise. Discreet devices that track alcohol levels could help people make more informed decisions about when to stop drinking and could potentially reduce alcohol-related road deaths.

'Transdermal' sensors ─ which rest against the skin and measure the amount of alcohol in perspiration ─ show the most promise as continuous alcohol sensors appropriate for widespread use, despite a time delay from when alcohol is consumed to when it can be detected transdermally. Ankle-worn transdermal sensors are already available, but their large and bulky design has limited their use to specific applications in research and the criminal justice system. Recently, advances in electronics and wireless communication have given rise to a new generation of wrist-worn sensors of smaller size and greater wearability.

In the first systematic evaluation of data from the new generation sensors, researchers from the University of Illinois at Urbana-Champaign used laboratory methods to compare prototypes of a wrist-worn device called BACtrack Skyn with AMS SCRAM, an established ankle-worn device. Thirty young adults wearing both devices received either a dose of alcohol intended to bring them up to the legal driving limit (target blood alcohol concentration 0.08%) or a non-alcoholic beverage as a control. Data from the Skyn device (worn on the inside of the wrist) were transmitted via Bluetooth to a custom smartphone app. Participants also provided regular breathlyzer readings until they left the lab.

Transdermal alcohol concentrations correlated strongly with breath alcohol concentrations, although with some (as yet unexplained) varability. Encouragingly, both the Skyn and SCRAM devices detected alcohol within 30-minutes of the start of the drinking period. However, as time progressed, the wrist-worn device generally responded faster than the ankle device; although transdermal alcohol concentrations lagged behind breath alcohol concentrations as expected, the lag time was significantly shorter for the wrist-worn devices than with SCRAM. Of note, failure rates for the Skyn prototypes and smartphone app were relatively high (18%-38%) compared with the non-prototype SCRAM devices (2%).

By providing preliminary evidence for the validity of the new-generation of wrist-worn sensor, the study takes an important first step for everyday drinkers seeking to monitor their alcohol intake. Although the lag time versus breath alcohol concentrations was modest (averaging around 24 minutes), advanced machine learning algorithms may in future reduce this further. However, the researchers caution that other key challenges remain before the devices are ready for real-world implementation. More reliable and robust prototypes will be required. Also, field testing in large and diverse groups of people drinking variable alcohol doses in real-world conditions will be necessary for comprehensive assessment of the relationhsip between transdermal and blood alcohol concentrations.

Source:
Journal reference:

Fairbairn, C.E & Kang, D. (2019) Temporal Dynamics of Transdermal Alcohol Concentration Measured via New‐Generation Wrist‐Worn Biosensor. Alcoholism: Clinical and Experimental Research. doi.org/10.1111/acer.14172.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
GLP-1 drugs, like semaglutide, lower risk of hospitalizations for alcohol use disorder